Compare MRK & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRK | SCLXW |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | N/A |
| IPO Year | 1994 | N/A |
| Metric | MRK | SCLXW |
|---|---|---|
| Price | $123.25 | $0.10 |
| Analyst Decision | Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $124.38 | N/A |
| AVG Volume (30 Days) | ★ 6.5M | 3.2K |
| Earning Date | 04-30-2026 | 03-07-2025 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 8.01 | N/A |
| EPS | ★ 7.28 | N/A |
| Revenue | ★ $65,011,000,000.00 | $55,152,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $5.42 | N/A |
| P/E Ratio | $16.33 | ★ N/A |
| Revenue Growth | 1.31 | ★ 22.02 |
| 52 Week Low | $75.40 | $0.04 |
| 52 Week High | $125.14 | $0.64 |
| Indicator | MRK | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 40.81 |
| Support Level | $113.27 | $0.09 |
| Resistance Level | $125.14 | $0.12 |
| Average True Range (ATR) | 2.67 | 0.02 |
| MACD | 0.49 | -0.00 |
| Stochastic Oscillator | 96.55 | 22.12 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.